<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911364</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1208-PR-0090</org_study_id>
    <secondary_id>2013-000063-91</secondary_id>
    <nct_id>NCT01911364</nct_id>
  </id_info>
  <brief_title>Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the triple combination of beclometasone
      dipropionate+Formoterol fumarate+Glycopyrrolate bromide is effective for the treatment of
      severe COPD patients (chronic obstructive pulmonary disease)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 52-WEEK, DOUBLE BLIND, DOUBLE DUMMY, RANDOMIZED, 3-ARM PARALLEL GROUP, ACTIVE CONTROLLED
      CLINICAL TRIAL OF FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE
      PLUS GLYCOPYRROLATE BROMIDE ADMINISTERED VIA PMDI (CHF 5993) VERSUS TIOTROPIUM BROMIDE AND
      VERSUS FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE ADMINISTERED
      VIA PMDI AND TIOTROPIUM BROMIDE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

      A total of 8 clinic visits (V0 to V7) will be performed during the study, as follows:

        -  A pre-screening visit (V0) to obtain the written informed consent from the patient

        -  A screening visit (V1) to establish the eligibility of patients, followed by a 2-week
           open-label run-in under Tiotropium

        -  After the randomisation (V2), patients will be assessed after 4, 12, 26, 40 and 52 weeks
           of treatment (V3 to V7) The assessments performed at visits include routine haematology
           and blood chemistry, medical history, physical examination, a 12-lead ECG, spirometric
           parameters, vital signs).

      During the run-in and the randomised treatment periods, patients use an e-diary to record
      symptoms, rescue medication use and compliance to the study medications daily.

      AEs/SAEs and COPD exacerbations will be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COPD exacerbation rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>Moderate and severe COPD exacerbation rate over 52 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pre-dose morning FEV1</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in pre-dose morning FEV1 at Week 52.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3686</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>BDP/FF/GB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium bromide 18 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP/FF + Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily
BDP/FF/GB versus BDP/FF + Tiotropium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP/FF/GB</intervention_name>
    <description>Superiority over Tiotropium</description>
    <arm_group_label>BDP/FF/GB</arm_group_label>
    <other_name>CHF 5993 pMDI 100/6/12.5 mcg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Superiority of CHF5993 over Tiotropium</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Spiriva 18 mcg 1 capsule o.d</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP/FF + Tiotropium</intervention_name>
    <description>non inferiority vs CHF5993</description>
    <arm_group_label>BDP/FF + Tiotropium</arm_group_label>
    <other_name>Foster 100/6 mcg 2 inhalations bid + Spiriva 18 mcg o.d.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female COPD patients aged ≥ 40 years

          -  Current smokers or ex-smokers

          -  FEV1&lt;50% predicted (FEV1/FVC &lt;0,7)

          -  at least 1 documented exacerbations in the last 12 Mo

        Exclusion Criteria:

          -  Pregnant or lactating women and all women physiologically capable of becoming pregnant

          -  Diagnosis of asthma, history of allergic rhinitis or atopy

          -  Patients treated for exacerbations 1 Mo prior to screening

          -  Patients treated with non-cardioselective β-blockers

          -  Patients treated with long-acting antihistamines

          -  Known respiratory disorders other than COPD

          -  Patients who have clinically significant cardiovascular condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorgen Vestbo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Respiratory Research Group, Wythenshawe Hospital, MANCHESTER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut für klinische Forschung</name>
      <address>
        <city>Hessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrád Megyei Mellkasi Betegségek Szakkórháza</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000063-91/results</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017 May 13;389(10082):1919-1929. doi: 10.1016/S0140-6736(17)30188-5. Epub 2017 Apr 3.</citation>
    <PMID>28385353</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Frequent exacerbators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

